JPH05507915A - 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途 - Google Patents

特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途

Info

Publication number
JPH05507915A
JPH05507915A JP91510110A JP51011091A JPH05507915A JP H05507915 A JPH05507915 A JP H05507915A JP 91510110 A JP91510110 A JP 91510110A JP 51011091 A JP51011091 A JP 51011091A JP H05507915 A JPH05507915 A JP H05507915A
Authority
JP
Japan
Prior art keywords
alkyl
disease
graves
independently
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91510110A
Other languages
English (en)
Japanese (ja)
Inventor
本坊　敏保
八郎 妹尾
西山　道久
Original Assignee
藤沢薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909012954A external-priority patent/GB9012954D0/en
Priority claimed from GB909012960A external-priority patent/GB9012960D0/en
Priority claimed from GB909012958A external-priority patent/GB9012958D0/en
Priority claimed from GB909012953A external-priority patent/GB9012953D0/en
Priority claimed from GB909012957A external-priority patent/GB9012957D0/en
Priority claimed from GB909012951A external-priority patent/GB9012951D0/en
Priority claimed from GB909012955A external-priority patent/GB9012955D0/en
Priority claimed from GB909012942A external-priority patent/GB9012942D0/en
Priority claimed from GB909012961A external-priority patent/GB9012961D0/en
Priority claimed from GB909012956A external-priority patent/GB9012956D0/en
Priority claimed from GB909012959A external-priority patent/GB9012959D0/en
Priority claimed from GB909012952A external-priority patent/GB9012952D0/en
Priority claimed from GB909017701A external-priority patent/GB9017701D0/en
Application filed by 藤沢薬品工業株式会社 filed Critical 藤沢薬品工業株式会社
Publication of JPH05507915A publication Critical patent/JPH05507915A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP91510110A 1990-06-11 1991-06-07 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途 Pending JPH05507915A (ja)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
GB9012953.7 1990-06-11
GB9012951.1 1990-06-11
GB909012958A GB9012958D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for hematic diseases
GB909012953A GB9012953D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for circulatory diseases
GB909012961A GB9012961D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for renal diseases
GB9012952.9 1990-06-11
GB909012951A GB9012951D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for collagen diseases
GB909012942A GB9012942D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for eosinophilic fasciitis
GB909012959A GB9012959D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for endocrine diseases
GB9012955.2 1990-06-11
GB9012956.0 1990-06-11
GB9012959.4 1990-06-11
GB9012954.5 1990-06-11
GB909012954A GB9012954D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for skin diseases
GB9012942.0 1990-06-11
GB9012960.2 1990-06-11
GB909012956A GB9012956D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for respiratory diseases
GB909012960A GB9012960D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for nervous diseases
GB909012952A GB9012952D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for adiposis
GB9012961.0 1990-06-11
GB909012955A GB9012955D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for eye diseases
GB909012957A GB9012957D0 (en) 1990-06-11 1990-06-11 New use of macrolide compounds for bone diseases
GB9012957.8 1990-06-11
GB9012958.6 1990-06-11
GB9017701.5 1990-08-13
GB909017701A GB9017701D0 (en) 1990-08-13 1990-08-13 New use of macrolide compounds for periodontal disease
PCT/JP1991/000768 WO1991019495A1 (fr) 1990-06-11 1991-06-07 Utilisation d'un compose de macrolide tel que le fk 506 pour fabriquer un medicament destine a traiter la purpura thrombocytopenique idiopathique et la maladie de basedow

Publications (1)

Publication Number Publication Date
JPH05507915A true JPH05507915A (ja) 1993-11-11

Family

ID=27584060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91510110A Pending JPH05507915A (ja) 1990-06-11 1991-06-07 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途

Country Status (3)

Country Link
EP (1) EP0533930A1 (fr)
JP (1) JPH05507915A (fr)
WO (1) WO1991019495A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
CA2091194A1 (fr) * 1992-04-08 1993-10-09 Richard D. Connell Derives 2-oxoethyliques utilises comme immunosuppresseurs
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
AU714254B2 (en) 1994-10-26 1999-12-23 Novartis Ag Pharmaceutical compositions
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
ES2367294T3 (es) 1998-03-26 2011-11-02 Astellas Pharma Inc. Preparación de liberación sostenida de un compuesto macrólido como tacrolimus.
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
EP1389480A1 (fr) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
US7014227B2 (en) * 2003-05-09 2006-03-21 The Langenau Manufacturing Company Wedge bar locking mechanism
EP2583678A3 (fr) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Immunopotentiateurs de petites molécules et dosages pour leur détection
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
EP1828202B1 (fr) 2004-12-20 2012-03-14 Wyeth LLC Analogues de rapamycine et leurs utilisations dans le traitement de troubles neurologiques, proliferatifs, et inflammatoires
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
ES2898849T3 (es) 2014-10-28 2022-03-09 Koushi Yamaguchi Medicamento para mejorar el síndrome de hipertensión inducida por el embarazo
CN106074367A (zh) * 2016-07-20 2016-11-09 中山大学中山眼科中心 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法
CA3108863A1 (fr) 2018-08-10 2020-02-13 Koushi Yamaguchi Agent therapeutique contre des maladies liees a l'immunite humorale dans la relation materno-foetale
CN113226331A (zh) 2018-12-18 2021-08-06 山口晃史 用于改善不孕不育症或妊娠状态的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
DE3853477T2 (de) * 1987-12-09 1995-11-09 Fisons Plc Makrozyklische verbindungen.
DK603988D0 (da) * 1988-10-28 1988-10-28 Klaus Bendtzen Farmaceutisk praeparat

Also Published As

Publication number Publication date
EP0533930A1 (fr) 1993-03-31
WO1991019495A1 (fr) 1991-12-26

Similar Documents

Publication Publication Date Title
JPH05507915A (ja) 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
JP3158437B2 (ja) 眼疾患に対するマクロライド化合物の使用
EP1056454B1 (fr) Utilisation de macrolides pour le traitement du glaucome
JP2002519378A (ja) 疼痛の治療剤または予防剤を製造するためのｆｋ５０６およびその類縁体の使用
JP3367105B2 (ja) 新規用途
AU687025B2 (en) Use of macrolides for the treatment of cerebral ischemia
GB2279006A (en) Treatment of amyotrophic lateral sclerosis
US5643901A (en) Medicament for treating idiopathic thrombocytopenic purpura
WO1991017754A1 (fr) Procedes servant a traiter et a prevenir une inflammation des muqueuses et des vaisseaux sanguins en utilisant du fk 506 et des composes connexes
ES2202130T3 (es) Uso de ciertos compuestos macrolidos para inducir diferenciacion condrogenica.
GB2249027A (en) Use of macrolide compounds for hepatic failure
CA2552305A1 (fr) Utilisation de macrolides pour le traitement ou la prevention de l'obstruction bronchique
GB2252041A (en) Use of macrolide compounds in treatment of autoimmune myocarditis
ES et al. VERWENDUNG VON MAKROLIDEN ZUR BEHANDLUNG VON AKUTEN LUNGENVERLETZUNGEN UTILISATION DE MACROLIDES POUR LE TRAITEMENT DES LESIONS DES POUMONS